REBIRTH Research Study

STUDY BASICS

Have you been diagnosed with Peripartum cardiomyopathy (PPCM)? You may be eligible to participate in a research study to determine the impact of bromocriptine therapy on myocardial recovery and subsequent clinical outcomes in a placebo controlled double blind randomized trial. Compensation is provided.

STUDY PURPOSE

The objective of REBIRTH is to determine the impact of bromocriptine therapy on myocardial recovery and subsequent clinical outcomes in a placebo controlled double blind randomized trial. There is evidence the earlier the treatment with bromocriptine, the more likely patients are to recover. 

COULD THIS STUDY BE RIGHT FOR YOU?

Women with a recent diagnosis of PPCM who are 18 years of age or older, within 5 months after delivery and not breastfeeding. Women who breastfeed may be eligible to be in group that does not take study drug.

WHAT PARTICIPANTS CAN EXPECT

• Entry study visit lasts approximately 2-2.5 hours
• Follow up visits at Month 1, Month 3, Month 6, Month 12 last approximately 1-1.5 hours
• Follow up visits at Month 24 and Month 36 can be done in-person or remotely
• Duration of participation: Approximately 3 years